Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of Stage 1 is to evaluate the safety of nivolumab consolidation after
completion of HD-MTX containing induction chemotherapy in older subjects with PCNSL in terms
of a tolerated dose (based on dose-limiting toxicities) for the expansion phase of the study
(Stage 2).The primary objective of Stage 2 is to evaluate the efficacy of nivolumab
consolidation after completion of HD-MTX containing induction chemotherapy in terms of the
2-year progression-free survival rate and compare to relevant historical controls